Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approachHsiao-Tzu Chien, Peter van Meer, Helen Prior et al.|Regulatory Toxicology and Pharmacology|2022Cited by 32
The use of recovery animals in nonclinical safety assessment studies with monoclonal antibodies: further 3Rs opportunities remainHelen Prior, Lucinda Weir, Laura Andrews et al.|Regulatory Toxicology and Pharmacology|2023Cited by 15
Methods: Implementation of<i>in vitro</i>and<i>ex vivo</i>phagocytosis and respiratory burst function assessments in safety testingWendy Freebern, Helen G. Haggerty, Tammy Bigwarfe et al.|Journal of Immunotoxicology|2012Cited by 12
Abstract LB-B33: Nonclinical safety evaluation of two distinct second generation variants of anti-CTLA4 monoclonal antibody, ipilimumab, in monkeysKaren Price, Michael J. Graziano, Courtni Newsome et al.|Molecular Cancer Therapeutics|2018Cited by 11
Current nonclinical approaches for immune assessments of immuno-oncology biotherapeuticsChristine Grimaldi, Diann Blanset, Alex Ibraghimov et al.|Drug Discovery Today|2022Cited by 7